297 related articles for article (PubMed ID: 36611948)
1. Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing.
Xiu K; Saunders L; Wen L; Ruan J; Dong R; Song J; Yang D; Zhang J; Xu J; Chen YE; Ma PX
Cells; 2022 Dec; 12(1):. PubMed ID: 36611948
[TBL] [Abstract][Full Text] [Related]
2. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
3. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
4. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
Wilbie D; Walther J; Mastrobattista E
Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
[TBL] [Abstract][Full Text] [Related]
5. Ultra-efficient delivery of CRISPR/Cas9 using ionic liquid conjugated polymers for genome editing-based tumor therapy.
Huang Z; Yang T; Yu J; Gao Y; Weng Y; Huang Y; Li S
Biomater Sci; 2024 Mar; 12(7):1716-1725. PubMed ID: 38344762
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
[TBL] [Abstract][Full Text] [Related]
7. Polyethylenimine based magnetic nanoparticles mediated non-viral CRISPR/Cas9 system for genome editing.
Rohiwal SS; Dvorakova N; Klima J; Vaskovicova M; Senigl F; Slouf M; Pavlova E; Stepanek P; Babuka D; Benes H; Ellederova Z; Stieger K
Sci Rep; 2020 Mar; 10(1):4619. PubMed ID: 32165679
[TBL] [Abstract][Full Text] [Related]
8. Functionalized PDA/DEX-PEI@HA nanoparticles combined with sleeping-beauty transposons for multistage targeted delivery of CRISPR/Cas9 gene.
Ma K; Li W; Zhu G; Sun S; Chi H; Yin Y; Diao H; Xing XJ; Guo Z; Wang L; Xu W; Cui C; Xu J
Biomed Pharmacother; 2021 Oct; 142():112061. PubMed ID: 34449313
[TBL] [Abstract][Full Text] [Related]
9. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
10. Smart arginine-equipped polycationic nanoparticles for p/CRISPR delivery into cells.
Moradi P; Hasanzadeh A; Radmanesh F; Rajai Daryasarei S; Hosseini ES; Kiani J; Shahbazi A; Nourizadeh H; Eslami M; Dorgalaleh A; Sahlolbei M; Hamblin MR; Karimi M
Nanotechnology; 2021 Nov; 33(7):. PubMed ID: 34727527
[TBL] [Abstract][Full Text] [Related]
11. Polymeric micellar nanoparticles for effective CRISPR/Cas9 genome editing in cancer.
Li Y; Li C; Yan J; Liao Y; Qin C; Wang L; Huang Y; Yang C; Wang J; Ding X; Yang YY; Yuan P
Biomaterials; 2024 Sep; 309():122573. PubMed ID: 38677222
[TBL] [Abstract][Full Text] [Related]
12. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
Verma R; Sahu R; Singh DD; Egbo TE
Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
[TBL] [Abstract][Full Text] [Related]
13. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
14. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
15. Reducible Branched Ester-Amine Quadpolymers (rBEAQs) Codelivering Plasmid DNA and RNA Oligonucleotides Enable CRISPR/Cas9 Genome Editing.
Rui Y; Wilson DR; Sanders K; Green JJ
ACS Appl Mater Interfaces; 2019 Mar; 11(11):10472-10480. PubMed ID: 30794383
[TBL] [Abstract][Full Text] [Related]
16. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
Xu Y; Liu R; Dai Z
Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
[TBL] [Abstract][Full Text] [Related]
17. Versatile Redox-Responsive Polyplexes for the Delivery of Plasmid DNA, Messenger RNA, and CRISPR-Cas9 Genome-Editing Machinery.
Wang Y; Ma B; Abdeen AA; Chen G; Xie R; Saha K; Gong S
ACS Appl Mater Interfaces; 2018 Sep; 10(38):31915-31927. PubMed ID: 30222305
[TBL] [Abstract][Full Text] [Related]
18. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
19. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
20. Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers.
Timin AS; Muslimov AR; Lepik KV; Epifanovskaya OS; Shakirova AI; Mock U; Riecken K; Okilova MV; Sergeev VS; Afanasyev BV; Fehse B; Sukhorukov GB
Nanomedicine; 2018 Jan; 14(1):97-108. PubMed ID: 28917642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
